Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 13/20 | 0.44 |
| ▸ | PPARG | P37231 | 11/20 | 0.44 |
| ▸ | PPARD | Q03181 | 10/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | IDE | P14735 | 1/20 | 0.39 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.38 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6035801 | 0.91 | PPARD (0.45) | PPARAPPARGPPARDSMN1; SMN2IDE | |
| SCHEMBL1634400 | 0.89 | PPARA (0.40) | PPARAPPARGPPARDSMN1; SMN2IDE | |
| SCHEMBL6034617 | 0.89 | PPARA (0.42) | PPARAPPARGPPARDSMN1; SMN2IDE | |
| SCHEMBL6035559 | 0.89 | PPARA (0.40) | PPARAPPARGPPARDSMN1; SMN2IDE | |
| SCHEMBL6035851 | 0.89 | PPARA (0.46) | PPARAPPARGPPARDSMN1; SMN2IDE | |
| SCHEMBL6035156 | 0.87 | PPARA (0.40) | PPARAPPARGPPARDSMN1; SMN2IDE | |
| SCHEMBL6034586 | 0.86 | PPARA (0.40) | PPARAPPARGPPARDSMN1; SMN2IDE | |
| SCHEMBL6035650 | 0.85 | PLA2G4B (0.39) | PPARAPPARGPPARDSMN1; SMN2IDE | |
| SCHEMBL6034603 | 0.85 | PPARA (0.41) | PPARAPPARGPPARDSMN1; SMN2IDE | |
| SCHEMBL6035033 | 0.81 | PPARA (0.52) | PPARAPPARGPPARDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-07-06 | — | — | US | disclosed |
| EP-1513817-A1 | 1, 2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | Takeda Pharmaceutical Company Limited (JP) | 2005-03-16 | — | — | EP | disclosed |
| WO-2003099793-A1 | 1,2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | GPR119, SLC5A1, CYP4B1 | PPARA 1717/4885PPARG 1037/4885PPARD 2488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.